Vise Technologies Inc. boosted its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 33.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,582 shares of the medical research company's stock after buying an additional 1,406 shares during the quarter. Vise Technologies Inc.'s holdings in Amgen were worth $1,455,000 at the end of the most recent quarter.
Other large investors have also bought and sold shares of the company. Centricity Wealth Management LLC acquired a new position in shares of Amgen in the 4th quarter valued at $25,000. Ritter Daniher Financial Advisory LLC DE boosted its position in Amgen by 66.2% during the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock worth $33,000 after acquiring an additional 51 shares during the period. Synergy Investment Management LLC acquired a new stake in Amgen during the 4th quarter worth about $34,000. Atala Financial Inc acquired a new stake in Amgen during the 4th quarter worth about $34,000. Finally, Heck Capital Advisors LLC acquired a new stake in Amgen during the 4th quarter worth about $36,000. Institutional investors own 76.50% of the company's stock.
Wall Street Analysts Forecast Growth
A number of brokerages have commented on AMGN. Wall Street Zen upgraded Amgen from a "buy" rating to a "strong-buy" rating in a research report on Sunday, May 18th. Erste Group Bank lowered Amgen from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 8th. Morgan Stanley restated an "equal weight" rating on shares of Amgen in a research report on Friday, May 2nd. Citigroup restated a "neutral" rating on shares of Amgen in a research report on Wednesday, February 5th. Finally, Royal Bank of Canada decreased their price objective on Amgen from $324.00 to $320.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Amgen currently has an average rating of "Hold" and a consensus price target of $309.22.
Get Our Latest Stock Report on AMGN
Amgen Stock Performance
Shares of AMGN stock traded up $7.79 during trading on Tuesday, reaching $279.45. The company had a trading volume of 2,917,052 shares, compared to its average volume of 2,796,422. The firm's 50 day simple moving average is $285.94 and its two-hundred day simple moving average is $285.86. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The company has a market capitalization of $150.26 billion, a PE ratio of 37.01, a PEG ratio of 2.63 and a beta of 0.51.
Amgen (NASDAQ:AMGN - Get Free Report) last released its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.18 by $0.72. The firm had revenue of $8.15 billion for the quarter, compared to analyst estimates of $8.05 billion. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The company's revenue was up 9.4% on a year-over-year basis. During the same quarter last year, the firm posted $3.96 EPS. Sell-side analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current year.
Amgen Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be given a $2.38 dividend. The ex-dividend date is Friday, May 16th. This represents a $9.52 annualized dividend and a yield of 3.41%. Amgen's dividend payout ratio (DPR) is currently 86.86%.
Amgen Profile
(
Free Report)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Read More
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
